Document Detail

CCR5 deletion protects against inflammation-associated mortality in dialysis patients.
MedLine Citation:
PMID:  19389855     Owner:  NLM     Status:  MEDLINE    
The CC-chemokine receptor 5 (CCR5) is a receptor for various proinflammatory chemokines, and a deletion variant of the CCR5 gene (CCR5 Delta 32) leads to deficiency of the receptor. We hypothesized that CCR5 Delta 32 modulates inflammation-driven mortality in patients with ESRD. We studied the interaction between CCR5 genotype and levels of high-sensitivity C-reactive protein (hsCRP) in 603 incident dialysis patients from the multicenter, prospective NEtherlands COoperative Study on the Adequacy of Dialysis (NECOSAD) cohort. CCR5 genotype and hsCRP levels were both available for 413 patients. During 5 yr of follow-up, 170 patients died; 87 from cardiovascular causes. Compared with the reference group of patients who had the wild-type CCR5 genotype and hsCRP <or= 10 mg/L (n = 225), those carrying the deletion allele with hsCRP <or= 10 mg/L (n = 55) had similar mortality, and those carrying the wild-type genotype with hsCRP > 10 mg/L (n = 108) had an increased risk for mortality (HR: 1.82; 95% CI: 1.29 to 2.58). However, those carrying the deletion allele with hsCRP > 10 mg/L (n = 25) had a mortality rate similar to the reference group; this seemingly protective effect of the CCR5 deletion was even more pronounced for cardiovascular mortality. We replicated these findings in an independent Swedish cohort of 302 ESRD patients. In conclusion, the CCR5 Delta 32 polymorphism attenuates the adverse effects of inflammation on overall and cardiovascular mortality in ESRD.
Friso L H Muntinghe; Marion Verduijn; Mike W Zuurman; Diana C Grootendorst; Juan Jesus Carrero; Abdul Rashid Qureshi; Karin Luttropp; Louise Nordfors; Bengt Lindholm; Vincent Brandenburg; Martin Schalling; Peter Stenvinkel; Elisabeth W Boeschoten; Raymond T Krediet; Gerjan Navis; Friedo W Dekker
Related Documents :
17571235 - Could we predict asymptomatic cardiovascular autonomic neuropathy in type 1 diabetic pa...
18614775 - Associations of kidney function with cardiovascular medication use after myocardial inf...
19705255 - Cardiovascular risk factors and outcome in patients with retinal vein occlusion.
20338495 - Alcohol consumption and mortality in patients with cardiovascular disease: a meta-analy...
9795045 - Reverse flow in intrahepatic portal vessels and liver function impairment in cirrhosis.
12538175 - Patients with a history of type ii heparin-induced thrombocytopenia with thrombosis req...
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2009-04-23
Journal Detail:
Title:  Journal of the American Society of Nephrology : JASN     Volume:  20     ISSN:  1533-3450     ISO Abbreviation:  J. Am. Soc. Nephrol.     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-07-01     Completed Date:  2009-07-27     Revised Date:  2013-06-02    
Medline Journal Info:
Nlm Unique ID:  9013836     Medline TA:  J Am Soc Nephrol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1641-9     Citation Subset:  IM    
University Medical Center Groningen, Department of Internal Medicine, Hanzeplein 1, PO Box 30001, 9700 RB Groningen, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
C-Reactive Protein / metabolism
Cardiovascular Diseases / complications,  metabolism
Cohort Studies
Follow-Up Studies
Gene Deletion*
Inflammation / complications*,  metabolism,  prevention & control*
Kaplan-Meier Estimate
Kidney Failure, Chronic / ethnology,  mortality*,  therapy*
Middle Aged
Polymorphism, Genetic / genetics
Prospective Studies
Receptors, CCR5 / genetics*,  metabolism
Renal Dialysis
Reg. No./Substance:
0/Receptors, CCR5; 9007-41-4/C-Reactive Protein
Comment In:
J Am Soc Nephrol. 2009 Jul;20(7):1429-31   [PMID:  19520751 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Reactive immunization suppresses advanced glycation and mitigates diabetic nephropathy.
Next Document:  Urine podocyte mRNAs mark progression of renal disease.